MaxCyte

MaxCyte OCF/Debt

The Operating Cash Flow to Debt Ratio of MaxCyte (MXCT) as of Nov 20, 2026 is -191.77 %. In the previous year, Operating Cash Flow to Debt Ratio was -153.10 % — a change of 25.26% (lower).

OCF/Debt

-191.77 %

YoY

25.26%

Last updated:

Operating Cash Flow to Debt Ratio of MaxCyte is 2025 -191.77 % . Operating Cash Flow to Debt Ratio of MaxCyte was 2024 -153.10 % . It decreases by 25.26% lower compared to the previous year.

The MaxCyte OCF/Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

OCF/Debt
Date
OCF/Debt
Jan 1, 2018
-207.41 USD
Jan 1, 2019
-122.07 USD
Jan 1, 2020
-126.06 USD
Jan 1, 2021
-187.95 USD
Jan 1, 2022
-91.85 USD
Jan 1, 2023
-115.70 USD
Jan 1, 2024
-153.10 USD
Jan 1, 2025
-191.77 USD
The MaxCyte OCF/Debt history
YEAROCF/DebtYoY
-191.77 %+25.26%
-153.10 %+32.32%
-115.70 %+25.97%
-91.85 %-51.13%
-187.95 %+49.09%
-126.06 %+3.28%
-122.07 %-41.15%
-207.41 %+7.82%
-192.37 %+312.48%
-46.64 %+1,203.21%
-3.58 %-90.87%
-39.19 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

MaxCyte Stock analysis

What does MaxCyte do? MaxCyte Inc is a US biotechnology company specializing in the development of platform-based technologies for the next generation of gene and cell therapies. They offer integrated platform technology for drug manufacturing, research, and development. Their proprietary platform technology, Flow ElectroporationTM, allows for efficient transduction of a variety of cells, making it a valuable tool for the production of CAR-T cell therapies. They also offer services for lentiviral production and customized gene therapy production. MaxCyte has secured $50 million in funding for expansion and has formed important partnerships in the industry. They are a leading player in the development of innovative technologies for gene and cell therapy products. MaxCyte is one of the most popular companies on Eulerpool.

Frequently Asked Questions about MaxCyte stock

Operating Cash Flow to Debt Ratio of MaxCyte is -191.77 % in 2025.

Operating Cash Flow to Debt Ratio of MaxCyte changed from -153.10 % to -191.77 %, representing a 25.26% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Operating Cash Flow to Debt Ratio MaxCyte since 2006 – with annual values, charts, and detailed analysis.

OCF/Debt measures what percentage of total debt can be covered by annual operating cash flow. Higher ratios indicate stronger debt repayment capacity.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Operating Cash Flow to Debt Ratio's MaxCyte with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — MaxCyte

All Key Metrics — MaxCyte